Medicines Co. suing Teva, Pliva on additional patent for anti-clotting drug Angiomax

Medicines Co. suing Teva, Pliva again over patent

NEW YORK — Drug maker Medicines Co. said Monday it is suing a unit of Teva Pharmaceutical Laboratories Inc. and Pliva Hrvatsk claiming infringement of another patent pertaining to the company’s anti-clotting agent Angiomax.

Medicines said it flied the lawsuits in U.S. District Court for the District of Delaware after Teva and Pliva asked the U.S. Food and Drug Administration to approve a generic version of Angiomax. Specifically, it is suing over the ‘343′ patent.

Medicines is already involved in lawsuits with the same companies over a separate patent on Angiomax.